Are you a PhD muscle or stem cell biologist interested to change paradigms and outcomes for rhabdomyosarcoma — a muscle cancer of children, adolescents and young adults? cc-TDI offers a mentored research experience in a multidisciplinary setting of biologist and engineers, nestled in a facility minutes from the Portland-area medical center and Intel headquarters in the Silicon Forest. Your research project in rhabdomyosarcoma could fundamentally change the way we think about and approach rare cancer research. Applicants can send their cv with 3 references to Dr. Charles Keller at firstname.lastname@example.org. about cc-TDI: Our approach has been to study childhood cancers in the context of development and postnatal regenerative biology. Highlights of our sarcoma research program include the first demonstration that many translocation-mediated oncogenes are not expressed at a constant level, but are expressed in a cell-cycle phase specific manner (G2 in the case of Pax3:Foxo1). We have also established that tumor-initiating mutations such as Pax3:Foxo1 are dispensable for tumor maintenance, but critically important for treatment resistance and tumor evolution through a process called checkpoint adaptation, which is borrowed by cancer cells from yeast. And although it might have seemed improbable at the onset, the cell-of-origin studies conducted by our laboratory have been the most informative in the development of potential new therapies for sarcomas. Specifically, our PLoS Genetics and Genes & Development publications below have resulted in 3 clinical trial concepts and trials for adults and children with rhabdomyosarcoma and the open pediatric phase I trial for entinostat [NCT02780804/ADVL1513, for which a phase IB cohort expansion for rhabdomyosarcoma is actively being planned]. Be inspired. Be innovative. Be part of our team!